Tazemetostat, an oral EZH2 inhibitor, is the first-in-class FDA-approved agent for epithelioid sarcoma and relapsed or refractory follicular lymphoma with EZH2 mutation [198]. The gene discussed is EZH2; the disease is follicular lymphoma.